KR100665919B1 - 4-옥소퀴놀린 화합물 및 hiv 인테그라제 저해제로서의그의 용도 - Google Patents
4-옥소퀴놀린 화합물 및 hiv 인테그라제 저해제로서의그의 용도 Download PDFInfo
- Publication number
- KR100665919B1 KR100665919B1 KR1020047010082A KR20047010082A KR100665919B1 KR 100665919 B1 KR100665919 B1 KR 100665919B1 KR 1020047010082 A KR1020047010082 A KR 1020047010082A KR 20047010082 A KR20047010082 A KR 20047010082A KR 100665919 B1 KR100665919 B1 KR 100665919B1
- Authority
- KR
- South Korea
- Prior art keywords
- oxo
- dihydroquinoline
- group
- carboxylic acid
- chloro
- Prior art date
Links
- 0 CC1C(CC(C=CC(C)(*2)OC)=CC2(C)N)CCCCCC1 Chemical compound CC1C(CC(C=CC(C)(*2)OC)=CC2(C)N)CCCCCC1 0.000 description 7
- NPZPDWKNQSIHTB-UHFFFAOYSA-N C=CC1N2C1C2 Chemical compound C=CC1N2C1C2 NPZPDWKNQSIHTB-UHFFFAOYSA-N 0.000 description 2
- WJYXCSVALZYNIK-UHFFFAOYSA-N CC(C)OC(c(c(Cl)c1)cc(I)c1OC(C)C)=O Chemical compound CC(C)OC(c(c(Cl)c1)cc(I)c1OC(C)C)=O WJYXCSVALZYNIK-UHFFFAOYSA-N 0.000 description 1
- FTLQVGYRTLTHGS-UHFFFAOYSA-N CC(C)OC(c(cc(c(OC(C)C)c1I)I)c1Cl)=O Chemical compound CC(C)OC(c(cc(c(OC(C)C)c1I)I)c1Cl)=O FTLQVGYRTLTHGS-UHFFFAOYSA-N 0.000 description 1
- PIGRFXLSCGGIAA-UHFFFAOYSA-N CCNCC1CC(C)CCCC1 Chemical compound CCNCC1CC(C)CCCC1 PIGRFXLSCGGIAA-UHFFFAOYSA-N 0.000 description 1
- ROSWBLUZDWVWPM-YFHOEESVSA-N CCOC(/C(/C(c1cc(I)cc(F)c1F)=O)=C\NCCO)=O Chemical compound CCOC(/C(/C(c1cc(I)cc(F)c1F)=O)=C\NCCO)=O ROSWBLUZDWVWPM-YFHOEESVSA-N 0.000 description 1
- VHJQQCNGVFOJFD-UHFFFAOYSA-N C[N]12C=CCC1C2 Chemical compound C[N]12C=CCC1C2 VHJQQCNGVFOJFD-UHFFFAOYSA-N 0.000 description 1
- URWBECKQVOLJJH-UHFFFAOYSA-N OC(C(CC(I)=C(C1)O)C1Cl)=O Chemical compound OC(C(CC(I)=C(C1)O)C1Cl)=O URWBECKQVOLJJH-UHFFFAOYSA-N 0.000 description 1
- OSBABFNFGBPWGL-UHFFFAOYSA-N OC(c(c(F)c1)cc(I)c1F)=O Chemical compound OC(c(c(F)c1)cc(I)c1F)=O OSBABFNFGBPWGL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
Claims (41)
- 활성 성분으로 하기 일반식 [I]의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염을 함유하는 항-HIV제:상기 식에서,환 Cy는 나프틸기, 또는 하기 그룹 A중에서 선택된 1 내지 5개의 치환체에 의해 치환되거나 비치환된 페닐기이되,그룹 A는 시아노기, 페닐기, 니트로기, 할로겐 원자, C1-4알킬기, 할로C1-4알킬기, 할로C1-4알킬옥시기, -ORa1, -SRa1, -NRa1Ra2, -CONRa1Ra2, -SO2NRa1Ra2, -NRa1CORa3, -SO2Ra3, -NRa1SO2Ra3 및 -COORa1 (여기에서, Ra1 및 Ra2는 동일하거나 상이하고 각각 수소 원자, C1-4알킬기 또는 벤질기이고, Ra3은 C1-4알킬기이다)로 이루어진 그룹이고;R1은 하기 그룹 B중에서 선택된 치환체, 또는 할로겐 원자 및 하기 그룹 B중에서 선택된 1 내지 3개의 치환체에 의해 치환된 C1-10알킬기이되,그룹 B는 페닐기 또는 1 내지 5개의 할로겐 원자에 의해 치환되거나 비치환된 페닐기, C3-6사이클로알킬기, 1 내지 3개의 C1-6알킬기에 의해 치환되거나 비치환되고, 벤젠환과 축합되거나 비축합된 5- 또는 6-원 헤테로사이클릭 그룹, -ORa4, -SRa4, -NRa4Ra5, -CONRa4Ra5, -SO2NRa4Ra5, -CORa6, -NRa4CORa6, -SO2Ra6, -NRa4SO2Ra6, -COORa4 및 -NRa5COORa6(여기에서, Ra4 및 Ra5는 동일하거나 상이하고 각각 수소 원자, C1-4알킬기 또는 페닐기이고, Ra6은 C1-4알킬기이다)로 구성된 그룹이고;R2는 수소 원자 또는 C1-4알킬기이고;R31은 수소 원자, 시아노기, 하이드록시기, 할로겐 원자 또는 C1-4알콕시기이고;X는 C-R32이고;Y는 C-R33 또는 질소 원자이되,R32 및 R33은 동일하거나 상이하고 각각 수소 원자, 시아노기, 할로겐 원자, 5- 또는 6-원 헤테로사이클릭 그룹, 1 내지 3개의 할로겐 원자에 의해 치환되거나 비치환된 C1-10알킬기, -ORa7, -SRa7, -NRa7Ra8, -NRa7CORa9, -COORa10 또는 -N=CH-NRa10Ra11(여기에서, Ra7 및 Ra8은 동일하거나 상이하고 각각 수소 원자, 페닐기, 또는 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기이고, Ra9는 C1-4알킬기이며, Ra10 및 Ra11은 동일하거나 상이하고 각각 수소 원자 또는 C1-4알킬기이다)이다.
- 제1항에 있어서, Y가 C-R33(여기에서, R33은 제1항에 정의된 바와 같다)인 항-HIV제.
- 제 1 항에 있어서, R2가 수소 원자인 항-HIV제.
- 일반식 [II]의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염:상기 식에서,R4 및 R6은 동일하거나 상이하고 각각 하기 그룹 A중에서 선택된 치환체이되,그룹 A는 시아노기, 페닐기, 니트로기, 할로겐 원자, C1-4알킬기, 할로C1-4알킬기, 할로C1-4알킬옥시기, -ORa1, -SRa1, -NRa1Ra2, -CONRa1Ra2, -SO2NRa1Ra2, -NRa1CORa3, -SO2Ra3, -NRa1SO2Ra3 및 -COORa1 (여기에서, Ra1 및 Ra2는 동일하거나 상이하고 각각 수소 원자, C1-4알킬기 또는 벤질기이고, Ra3은 C1-4알킬기이다)로 이루어진 그룹이고;R5는 수소 원자 및 상기 그룹 A중에서 선택된 치환체이고;m은 0 또는 1 내지 3의 정수이고, m이 2 또는 3인 경우 각 m의 R6은 동일하거나 상이할 수 있고;R1은 하기 그룹 B중에서 선택된 치환체, 또는 할로겐 원자 및 하기 그룹 B중에서 선택된 1 내지 3개의 치환체에 의해 치환된 C1-10알킬기이되,그룹 B는 페닐기 또는 1 내지 5개의 할로겐 원자에 의해 치환되거나 비치환된 페닐기, C3-6사이클로알킬기, 1 내지 3개의 C1-6알킬기에 의해 치환되거나 비치환되고, 벤젠환과 축합되거나 비축합된 5- 또는 6-원 헤테로사이클릭 그룹, -ORa4, -SRa4, -NRa4Ra5, -CONRa4Ra5, -SO2NRa4Ra5, -CORa6, -NRa4CORa6, -SO2Ra6, -NRa4SO2Ra6, -COORa4 및 -NRa5COORa6(여기에서, Ra4 및 Ra5는 동일하거나 상이하고 각각 수소 원자, C1-4알킬기 또는 페닐기이고, Ra6은 C1-4알킬기이다)로 구성된 그룹이고;R31은 수소 원자, 시아노기, 하이드록시기, 할로겐 원자 또는 C1-4알콕시기이고;R32 및 R33은 동일하거나 상이하고 각각 수소 원자, 시아노기, 할로겐 원자, 5- 또는 6-원 헤테로사이클릭 그룹, 1 내지 3개의 할로겐 원자에 의해 치환되거나 비치환된 C1-10알킬기, -ORa7, -SRa7, -NRa7Ra8, -NRa7CORa9, -COORa10 또는 -N=CH-NRa10Ra11(여기에서, Ra7 및 Ra8은 동일하거나 상이하고 각각 수소 원자, 페닐기, 또는 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기이고, Ra9는 C1-4알킬기이며, Ra10 및 Ra11은 동일하거나 상이하고 각각 수소 원자 또는 C1-4알킬기이다)이다.
- 제 5 항에 있어서, R31이 수소 원자, 시아노기, 하이드록시기 또는 C1-4 알콕시기인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 6 항에 있어서, R31이 수소 원자인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 5 항에 있어서,R32 및 R33이 동일하거나 상이하고 각각 수소 원자, 시아노기, 할로겐 원자, 5- 또는 6-원 헤테로사이클릭 그룹, 1 내지 3개의 할로겐 원자에 의해 치환되거나 비치환된 C1-10알킬기, -ORa7, -SRa7, -NRa7Ra8, -NRa7CORa9, -COORa10 또는 -N=CH-NRa10Ra11(여기에서, Ra7 및 Ra8은 동일하거나 상이하고 각각 수소 원자, 페닐기, 또는 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기이고, Ra9는 C1-4알킬기이며, Ra10 및 Ra11은 동일하거나 상이하고 각각 수소 원자 또는 C1-4알킬기이다)인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 5 항에 있어서,R32가 수소 원자, 시아노기, 할로겐 원자, 5- 또는 6-원 헤테로사이클릭 그룹, 1 내지 3개의 할로겐 원자에 의해 치환되거나 비치환된 C1-10알킬기, -ORa7, -SRa7, -NRa7Ra8, -COORa10 또는 -N=CH-NRa10Ra11(여기에서, Ra7 및 Ra8은 동일하거나 상이하고 각각 수소 원자, 또는 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기이고, Ra10 및 Ra11은 동일하거나 상이하고 각각 수소 원자 또는 C1-4알킬기이다)인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 9 항에 있어서,R32가 수소 원자, -ORa7 또는 -NRa7Ra8(여기에서, Ra7 및 Ra8은 동일하거나 상이하고 각각 수소 원자, 또는 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기이다)인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 8 항에 있어서,R33이 수소 원자, 1 내지 3개의 할로겐 원자에 의해 치환되거나 비치환된 C1-10알킬기, -ORa7, -NRa7Ra8 또는 -NRa7CORa9(여기에서, Ra7 및 Ra8은 동일하거나 상이하고 각각 수소 원자, 페닐기, 또는 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기이고, Ra9는 C1-4알킬기이다)인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 11 항에 있어서,R33이 수소 원자, -ORa7 또는 -NRa7Ra8(여기에서, Ra7 및 Ra8은 동일하거나 상이하고 각각 수소 원자, 페닐기, 또는 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기이다)인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 8 항에 있어서,Ra7 및 Ra8이 동일하거나 상이하고 각각 C3-6사이클로알킬기 또는 하이드록시기에 의해 치환되거나 비치환된 C1-10알킬기인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 5 항에 있어서,R4 및 R5이 동일하거나 상이하고 각각 시아노기, 페닐기, 니트로기, 할로겐 원자, C1-4알킬기, 할로C1-4알킬기, 할로C1-4알킬옥시기, -ORa1, -NRa1Ra2, -CONRa1Ra2, -SO2NRa1Ra2, -NRa1CORa3, -SO2Ra3, -NRa1SO2Ra3 및 -COORa1(여기에서, Ra1 및 Ra2는 동일하거나 상이하고 각각 수소 원자, C1-4알킬기 또는 벤질기이고, Ra3은 C1-4알킬기이다)중에서 선택된 치환체인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 14 항에 있어서,R4가 페닐기, 할로겐 원자, C1-4알킬기, 할로C1-4알킬옥시기, -ORa1, -NRa1Ra2, -SO2NRa1Ra2, -NRa1CORa3, -SO2Ra3, -NRa1SO2Ra3 또는 -COORa1(여기에서, Ra1 및 Ra2는 동일하거나 상이하고 각각 수소 원자, C1-4알킬기 또는 벤질기이고, Ra3은 C1-4알킬기이다)인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 15 항에 있어서, R4가 할로겐 원자인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 5 항에 있어서, R5가 수소 원자, 시아노기, 페닐기, 니트로기, 할로겐 원자, C1-4알킬기, 할로C1-4알킬기, 할로C1-4알킬옥시기, -ORa1, -NRa1Ra2, -CONRa1Ra2, -SO2NRa1Ra2, -NRa1CORa3 또는 SO2Ra3(여기에서, Ra1 및 Ra2는 동일하거나 상이하고 각각 수소 원자 또는 C1-4알킬기이고, Ra3은 C1-4알킬기이다)인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 5 항에 있어서, R6이 할로겐 원자인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 5 항에 있어서, m이 0 또는 1인 4-옥소퀴놀린 화합물 또는 그의 약제학적 으로 허용되는 염.
- 제 5 항에 있어서,R1이 페닐기 또는 1 내지 5개의 할로겐 원자에 의해 치환되거나 비치환된 페닐기, C3-6사이클로알킬기, -NRa4Ra5, -NRa4CORa6, -NRa4SO2Ra6, -NRa5COORa6(여기에서, Ra4 및 Ra5는 동일하거나 상이하고 각각 수소 원자, C1-4알킬기 또는 페닐기이고, Ra6은 C1-4알킬기이다), 또는 할로겐 원자 및 그룹 B(제5항에 정의된 바와 같다)중에서 선택된 1 내지 3개의 치환체에 의해 치환된 C1-10알킬기인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 20 항에 있어서,R1이 할로겐 원자 및 그룹 B(제5항에 정의된 바와 같다)중에서 선택된 1 내지 3개의 치환체에 의해 치환된 C1-10알킬기인 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염.
- 제 5 항에 있어서,6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린- 3-카복실산 (실시예 1-1),6-(2,3-디클로로벤질)-8-플루오로-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-2),6-(2,3-디클로로벤질)-1-(2-메탄설포닐아미노에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-3),6-(2,3-디클로로벤질)-1-(2-이미다졸-1-일에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-4),6-(2,3-디클로로벤질)-1-디메틸카바모일메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-5),6-(2,3-디클로로벤질)-1-메틸카바모일메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-6),1-카바모일메틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-7),6-(2,3-디클로로벤질)-1-이소프로필-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-8),6-(2,3-디클로로벤질)-4-옥소-1-설파모일메틸-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-9),1-(2-카복시에틸)-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-10),1-(2-하이드록시에틸)-6-나프탈렌-1-일메틸-4-옥소-1,4-디하이드로퀴놀린-3- 카복실산 (실시예 1-11),6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 메틸 에스테르 (실시예 1-12),1-(2-카바모일에틸)-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-13),6-(2,3-디클로로벤질)-4-옥소-1-(2-옥소프로필)-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-14),1-벤질-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-15),6-(2,3-디클로로벤질)-4-옥소-1-펜에틸-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-16),6-(2,3-디클로로벤질)-1-(3-페닐프로필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-17),6-(2,3-디클로로벤질)-1-이소부틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-18),6-(2,3-디클로로벤질)-1-(4-페닐부틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-19),1-비페닐-2-일메틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-20),6-(2,3-디클로로벤질)-1-(4-하이드록시부틸)-4-옥소-1,4-디하이드로퀴놀린- 3-카복실산 (실시예 1-21),1-벤조[b]티오펜-2-일메틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-22),6-(2,3-디클로로벤질)-1-(3,4-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-23),6-(2,3-디클로로벤질)-1-(2-디메틸아미노에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-24),6-(2,3-디클로로벤질)-1-(3-하이드록시프로필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-25),6-(2,3-디클로로벤질)-1-(2-메톡시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-26),6-(2,3-디클로로벤질)-1-(2,2,2-트리플루오로에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-27),1-카복시메틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-28),6-(2,3-디클로로벤질)-1-[2-(4-메틸티아졸-5-일)에틸]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-29),6-(2,3-디클로로벤질)-1-(2-하이드록시프로필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-30),6-(2,3-디클로로벤질)-1-(2-메틸설파닐에틸)-4-옥소-1,4-디하이드로퀴놀린- 3-카복실산 (실시예 1-32),6-(2-클로로-6-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-33),6-(2,3-디클로로벤질)-1-(5-하이드록시펜틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-34),6-(2,3-디클로로벤질)-1-(2-모르폴린-4-일에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-35),6-(2,3-디클로로벤질)-1-메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-36),6-(2,3-디클로로벤질)-1-에틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-37),6-(2,3-디클로로벤질)-4-옥소-1-프로필-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-38),1-부틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-39),1-사이클로펜틸메틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-40),6-(2,3-디클로로벤질)-1-(2-메탄설포닐에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-41),1-사이클로헥실메틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3- 카복실산 (실시예 1-42),6-(2,3-디클로로벤질)-1-(2-하이드록시-2-페닐에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-43),6-(2,3-디클로로벤질)-1-(2-플루오로에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-44),6-(2,3-디클로로벤질)-4-옥소-1-(2-피리딘-2-일에틸)-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-45),1-(2-아미노에틸)-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-46),6-(2,3-디클로로벤질)-1-(2-하이드록시-2-메틸프로필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-47),1-(2-아세틸아미노에틸)-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-48),6-(2,3-디클로로벤질)-1-(2-에톡시카보닐아미노에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-49),6-(2,3-디플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-50),6-(2-클로로-4-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-51),6-(2-클로로벤질)-4-옥소-1-펜에틸-1,4-디하이드로퀴놀린-3-카복실산 (실시 예 1-65),6-(2-클로로-3-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-66),6-(2,3-디클로로벤질)-1-메틸설파닐메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-68),6-(2,3-디클로로벤질)-1-메탄설포닐메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-69),1-t-부틸설파모일메틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-70),6-(2,3-디클로로벤질)-1-메틸설파모일메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-71),6-(2,3-디클로로벤질)-1-디메틸설파모일메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-72),6-(2-클로로-3,6-디플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-73),6-(2,3-디클로로벤질)-1-(2,3-디하이드록시프로필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-74),6-(2-클로로-6-플루오로벤질)-1-설파모일메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-75),6-(2-클로로-6-플루오로벤질)-1-메틸설파모일메틸-4-옥소-1,4-디하이드로퀴 놀린-3-카복실산 (실시예 1-76),6-(2-클로로-6-플루오로벤질)-1-디메틸설파모일메틸-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-77),6-(2-클로로-3-메틸벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-79),6-(2-브로모벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-80),6-(2-클로로-3-메톡시벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-82),1-(2-하이드록시에틸)-6-(2-메탄설포닐벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-85),6-비페닐-2-일메틸-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-86),6-(2-클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-87),6-(2-클로로-5-메틸설파닐벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-92),1-(2-하이드록시에틸)-4-옥소-6-(2-트리플루오로메틸옥시벤질)-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-93),6-(2-클로로-5-메틸벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀 린-3-카복실산 (실시예 1-97),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-99),6-(3-클로로-2,6-디플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-100),6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-101),1-사이클로프로필-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 1-102),1-아미노-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 2-1),6-(2,3-디클로로벤질)-1-메톡시카보닐아미노-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 2-2),1-아세틸아미노-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 2-3),6-(2,3-디클로로벤질)-1-메탄설포닐아미노-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 2-4),6-(2,3-디클로로벤질)-1-(N-메탄설포닐-N-메틸아미노)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 2-5),6-(2,3-디클로로벤질)-1-디메틸아미노-4-옥소-1,4-디하이드로퀴놀린-3-카복 실산 (실시예 2-6),6-(2,3-디클로로벤질)-1-메틸아미노-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 2-7),6-(2,3-디클로로벤질)-1-에틸아미노-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 2-8),6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-5-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-1),6-(3-클로로-2-메틸벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-2),6-(3-클로로-2-메톡시벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-3),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-4),6-(2,3-디클로로벤질)-5-하이드록시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-5),6-(2,3-디클로로벤질)-7-하이드록시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-6),1-(2-하이드록시에틸)-6-(2-메틸아미노벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-7),6-(2-디메틸아미노벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린 -3-카복실산 (실시예 3-8),6-(2,3-디클로로벤질)-4-옥소-1-페닐-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-9),6-(2,3-디클로로벤질)-1-[2-하이드록시-1-(하이드록시메틸)에틸]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-10),1-사이클로부틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-12),1-사이클로펜틸-6-(2,3-디클로로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-13),6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-14),6-(2-디메틸설파모일벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-16),6-(3-클로로-2,4-디플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-17),6-(2-카복시벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-18),1-(2-하이드록시에틸)-6-(2-메틸설파모일벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-19),6-(2,3-디클로로벤질)-7-에톡시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드 로퀴놀린-3-카복실산 (실시예 3-20),7-클로로-6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-21),6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-4-옥소-7-트리플루오로메틸-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-22),(S)-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시-1-메틸에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-23),(R)-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시-1-메틸에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-24),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-8-트리플루오로메틸-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-25),6-(3-클로로-2-플루오로벤질)-1-[2-하이드록시-1-(하이드록시메틸)에틸]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-26),7-시아노-6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-27),6-(2-에틸메틸아미노벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-28),6-[2-(N-메틸-N-프로필아미노)벤질]-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-29),6-[2-(N-벤질-N-메틸아미노)벤질]-1-(2-하이드록시에틸)-4-옥소-1,4-디하이 드로퀴놀린-3-카복실산 (실시예 3-30),6-[2-(N-메탄설포닐-N-메틸아미노)벤질]-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-31),6-[2-(N-이소프로필-N-메틸아미노)벤질]-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-32),1-t-부틸-6-(3-클로로-2-플루오로벤질)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-33),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-34),8-아미노-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-35),7-카복시-6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-36),6-(3-클로로-2,6-디플루오로벤질)-1-(2-하이드록시에틸)-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-37),6-(3-클로로-2-플루오로벤질)-8-디메틸아미노-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-38),8-아세틸아미노-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-39),5-시아노-6-(2,3-디클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드 로퀴놀린-3-카복실산 (실시예 3-40),6-[2-(N-아세틸-N-메틸아미노)벤질]-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-41),6-(2-디에틸아미노벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-42),6-(3-클로로-2-플루오로벤질)-1-(1,1-디메틸-2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-43),6-(3-클로로-2-플루오로벤질)-7-에톡시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-44),6-(3-클로로-2-플루오로벤질)-7,8-디메톡시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-45),6-(3-클로로-2-플루오로벤질)-8-에톡시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-47),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-8-메틸아미노-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-48),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-7-프로필옥시-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-49),6-(3-클로로-2-플루오로벤질)-7-(디메틸아미노메틸렌아미노)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-50),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-7-메톡시-4-옥소-1,4-디 하이드로퀴놀린-3-카복실산 메틸 에스테르 (실시예 3-51),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-8-페녹시-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-52),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-7-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-53),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-8-프로필아미노-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-54),6-(3-클로로-2-플루오로벤질)-8-에틸아미노-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-55),(S)-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시-1-메틸에틸)-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-56),(S)-6-(3-클로로-2,6-디플루오로벤질)-1-(2-하이드록시-1-메틸에틸)-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-57),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-8-프로필옥시-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-58),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-8-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-59),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-60),(S)-6-(3-클로로-2-플루오로벤질)-7-에톡시-1-(2-하이드록시-1-메틸에틸)-4- 옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-61),6-(3-클로로-2-플루오로벤질)-7-디메틸아미노-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-62),6-(3-클로로-2-플루오로벤질)-7-사이클로헥실메톡시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-63),6-(3-클로로-2-플루오로벤질)-8-디에틸아미노-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-64),6-(3-클로로-2-플루오로벤질)-7-메틸아미노-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-65),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-7-피롤리딘-1-일-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-66),(S)-6-(3-클로로-2-플루오로벤질)-8-에톡시-1-(2-하이드록시-1-메틸에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-67),(S)-6-(3-클로로-2-플루오로벤질)-7-에톡시-1-[1-(하이드록시메틸)프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-68),6-(3-클로로-2-플루오로벤질)-8-사이클로헥실메톡시-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-69),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-2-메틸프로필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-70),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-3-메틸부틸)-4-옥소- 1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-71),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)프로필]-7-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-72),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)프로필]-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-73),(S)-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시-1-메틸에틸)-7-이소프로필-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-74),(S)-6-(3-클로로-2-플루오로벤질)-1-[2,2-디메틸-1-(하이드록시메틸)프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-75),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-7-(2-하이드록시에틸옥시)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-76),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-7-(3-하이드록시프로필옥시)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-77),6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시에틸)-8-(2-하이드록시에틸아미노)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-78),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)프로필]-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-79),(S)-6-(3-클로로-2-플루오로벤질)-8-디메틸아미노-1-(2-하이드록시-1-메틸에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-80),(S)-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시-1-페닐에틸)-4-옥소-1,4- 디하이드로퀴놀린-3-카복실산 (실시예 3-81),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)부틸]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-82),6-(3-클로로-2-플루오로벤질)-1-((1S,2S)-1-하이드록시메틸-2-메틸부틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-83),(S)-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시-1-메틸에틸)-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-84),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-벤질-2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 3-85),6-(2-클로로-5-메탄설포닐벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-1),6-(2-에틸벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-4),6-(2-클로로-5-메틸벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-5),6-(2-클로로-5-플루오로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-6),6-(5-브로모-2-클로로벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-7),6-(2,3-디클로로벤질)-7-플루오로-1-(2-하이드록시에틸)-4-옥소-1,4-디하이 드로퀴놀린-3-카복실산 (실시예 4-9),6-(2-클로로-5-하이드록시벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-11),6-(2,3-디클로로벤질)-5-플루오로-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-12),6-(2-에톡시벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-13),6-(2-하이드록시벤질)-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-14),6-(2,3-디클로로벤질)-7-메틸-1-(2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-15),(S)-6-(3-클로로-2-플루오로벤질)-1-(2-하이드록시-1-메틸에틸)-8-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-16),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)프로필]-8-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-17),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-사이클로헥실-2-하이드록시에틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-18),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-2-메틸프로필)-7-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-19),(S)-6-(3-클로로-2-플루오로벤질)-1-[2,2-디메틸-1-(하이드록시메틸)프로필] -7-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-20),(S)-6-(3-클로로-2-플루오로벤질)-8-에톡시-1-[1-(하이드록시메틸)프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-21),(S)-6-(3-클로로-2-플루오로벤질)-1-[2-사이클로헥실-1-(하이드록시메틸)에틸]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-22),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-3-메틸부틸)-7-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-23),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-2-메틸프로필)-8-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-24),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-3-메틸부틸)-8-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-25),(S)-6-(3-클로로-2-플루오로벤질)-[2,2-디메틸-1-(하이드록시메틸)프로필]-8-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-26),6-(3-클로로-2-플루오로벤질)-1-((1S,2S)-1-하이드록시메틸-2-메틸부틸)-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-27),6-(3-클로로-2-플루오로벤질)-7-에톡시-1-((1S,2S)-1-하이드록시메틸-2-메틸부틸)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-28),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)프로필]-7-메틸설파닐-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-29),(S)-6-(3-클로로-2-플루오로벤질)-7-에톡시-1-(1-하이드록시메틸-2-메틸프로 필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-30),(S)-6-(3-클로로-2-플루오로벤질)-7-에톡시-1-[2,2-디메틸-1-(하이드록시메틸)프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-31),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-2-메틸프로필)-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-32),(S)-6-(3-클로로-2-플루오로벤질)-1-[2,2-디메틸-1-(하이드록시메틸)프로필]-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-33),(S)-6-(3-클로로-2-플루오로벤질)-1-[2,2-디메틸-1-(하이드록시메틸)프로필]-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-34),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)부틸]-7-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-35),(S)-6-(3-클로로-2-플루오로벤질)-7-에톡시-1-[1-(하이드록시메틸)부틸]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-36),(S)-6-(3-클로로-2-플루오로벤질)-8-에톡시-1-[2,2-디메틸-1-(하이드록시메틸)프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-37),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)부틸]-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-38),6-(3-클로로-2-플루오로벤질)-1-((1S,2S)-1-하이드록시메틸-2-메틸부틸)-7-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-39),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-사이클로헥실-2-하이드록시에틸)-7- 이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-40),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-사이클로헥실-2-하이드록시에틸)-8-에톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-41),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-사이클로헥실-2-하이드록시에틸)-7-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-42),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-사이클로헥실-2-하이드록시에틸)-7-에톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-43),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-사이클로헥실-2-하이드록시에틸)-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-44),(S)-6-(3-클로로-2-플루오로벤질)-8-에톡시-1-(1-하이드록시메틸-2-메틸프로필)-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-45),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-하이드록시메틸-2-메틸프로필)-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-46),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)부틸]-8-이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-47),(S)-6-(3-클로로-2-플루오로벤질)-8-에톡시-1-[1-(하이드록시메틸)부틸]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-48),(S)-6-(3-클로로-2-플루오로벤질)-1-[1-(하이드록시메틸)부틸]-8-메톡시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-49),(S)-6-(3-클로로-2-플루오로벤질)-1-(1-사이클로헥실-2-하이드록시에틸)-8- 이소프로필옥시-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-50) 및(S)-6-(3-클로로-2-플루오로벤질)-1-[2,2-디메틸-1-(하이드록시메틸)프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산 (실시예 4-52)로 구성된 그룹중에서 선택되는 4-옥소퀴놀린 화합물 또는 이들의 약제학적으로 허용되는 염.
- 삭제
- 삭제
- 활성 성분으로서 제 5 항 내지 22 항중 어느 한 항의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염을 함유하는 항바이러스제.
- 활성 성분으로서 제 5 항 내지 22 항중 어느 한 항의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염을 함유하는 항-HIV제.
- 활성 성분으로서 제 1 항 내지 22 항중 어느 한 항의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염과 다른 항-HIV 활성 물질을 함유하는 항-HIV 조성물.
- 다른 항-HIV제(들)와 함께 다중 약제 배합 치료하기 위한, 활성 성분으로서 제 1 항 내지 22 항중 어느 한 항의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염을 함유하는 항-HIV제.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 5 항 내지 22 항중 어느 한 항의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염과 약제학적으로 허용되는 담체를 포함하는 항-HIV 조성물.
- 삭제
- 제 5 항 내지 22 항중 어느 한 항의 4-옥소퀴놀린 화합물 또는 그의 약제학적으로 허용되는 염과 약제학적으로 허용되는 담체를 포함하는 항바이러스성 조성물.
- 제 36 항의 조성물과 이 조성물이 HIV 감염 질환의 예방 또는 치료를 위해 사용될 수 있거나 사용되어야 한다는 문구를 포함하는 상업용 포장.
- 제 37 항의 조성물과 이 조성물이 HIV 인테그라제 저해를 위해 사용될 수 있거나 사용되어야 한다는 문구를 포함하는 상업용 포장.
- 제 38 항의 조성물과 이 조성물이 바이러스성 감염 질환의 예방 또는 치료를 위해 사용될 수 있거나 사용되어야 한다는 문구를 포함하는 상업용 포장.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002336843 | 2002-11-20 | ||
JPJP-P-2002-00336843 | 2002-11-20 | ||
JPJP-P-2003-00065807 | 2003-03-11 | ||
JP2003065807 | 2003-03-11 | ||
JPJP-P-2003-00139616 | 2003-05-16 | ||
JP2003139616 | 2003-05-16 | ||
PCT/JP2003/014773 WO2004046115A1 (ja) | 2002-11-20 | 2003-11-20 | 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040081443A KR20040081443A (ko) | 2004-09-21 |
KR100665919B1 true KR100665919B1 (ko) | 2007-03-08 |
Family
ID=32329647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047010082A KR100665919B1 (ko) | 2002-11-20 | 2003-11-20 | 4-옥소퀴놀린 화합물 및 hiv 인테그라제 저해제로서의그의 용도 |
Country Status (32)
Country | Link |
---|---|
US (6) | US7176220B2 (ko) |
EP (5) | EP2272516A3 (ko) |
KR (1) | KR100665919B1 (ko) |
AR (2) | AR042095A1 (ko) |
AT (1) | ATE443048T1 (ko) |
AU (1) | AU2003302029B8 (ko) |
BE (1) | BE2013C063I2 (ko) |
BR (1) | BRPI0306214B1 (ko) |
CA (1) | CA2470365C (ko) |
CY (2) | CY1110690T1 (ko) |
CZ (1) | CZ2004764A3 (ko) |
DE (1) | DE60329318D1 (ko) |
DK (1) | DK1564210T5 (ko) |
ES (1) | ES2329240T3 (ko) |
FR (1) | FR13C0061I2 (ko) |
HK (1) | HK1080852A1 (ko) |
HU (1) | HUS1300066I1 (ko) |
IL (2) | IL162548A0 (ko) |
LT (1) | LTPA2013018I1 (ko) |
LU (1) | LU92307I2 (ko) |
MX (1) | MXPA04006553A (ko) |
MY (1) | MY136173A (ko) |
NO (3) | NO327098B1 (ko) |
NZ (1) | NZ533641A (ko) |
PE (1) | PE20040840A1 (ko) |
PT (1) | PT1564210E (ko) |
SI (1) | SI1564210T1 (ko) |
SK (1) | SK2662004A3 (ko) |
TR (1) | TR200401663T1 (ko) |
TW (1) | TWI248928B (ko) |
WO (1) | WO2004046115A1 (ko) |
ZA (1) | ZA200404537B (ko) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL212914B1 (pl) | 2001-10-26 | 2012-12-31 | Angeletti P Ist Richerche Bio | N-podstawione hydroksypirymidynonokarboksyamidy jako inhibitory integrazy HIV |
DK1564210T5 (da) * | 2002-11-20 | 2010-05-03 | Japan Tobacco Inc | 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer |
US7776883B2 (en) | 2004-03-10 | 2010-08-17 | The United States Of America As Represented By The Department Of Health And Human Services | Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC) |
MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
WO2006033422A1 (ja) * | 2004-09-21 | 2006-03-30 | Japan Tobacco Inc. | キノリジノン化合物、およびそのhivインテグラーゼ阻害剤としての利用 |
US7745459B2 (en) | 2004-09-21 | 2010-06-29 | Japan Tobacco Inc. | Quinolizinone compound and use thereof as HIV integrase inhibitor |
UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US20070032522A1 (en) * | 2005-07-01 | 2007-02-08 | Kumar Dange V | Antiviral agents |
WO2007063869A1 (ja) * | 2005-11-30 | 2007-06-07 | Japan Tobacco Inc. | 高純度キノロン化合物の製造方法 |
CA2635468C (en) * | 2005-12-30 | 2016-08-09 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
AU2013203476C1 (en) * | 2005-12-30 | 2016-11-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
AU2007223260C1 (en) | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
IN2014CN00532A (ko) * | 2006-03-06 | 2015-04-03 | Japan Tobacco Inc | |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
CN103275033B (zh) | 2006-07-07 | 2015-04-29 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
EP2046328A4 (en) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY |
EP2644587A3 (en) * | 2006-09-12 | 2013-10-23 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
MX2009003410A (es) | 2006-09-29 | 2009-07-17 | Idenix Pharmaceuticals Inc | Fosfoindoles enantiomericamente puros como inhibidores de vih. |
DK2114903T3 (da) | 2006-12-22 | 2011-04-18 | Avexa Ltd | Bicykliske pyrimidinoner og anvendelser deraf |
US9891239B2 (en) * | 2007-02-23 | 2018-02-13 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20090093482A1 (en) * | 2007-06-29 | 2009-04-09 | Gilead Sciences, Inc. | Therapeutic compositions and methods |
SG182229A1 (en) * | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
EP2197847B1 (en) | 2007-09-12 | 2012-11-07 | Concert Pharmaceuticals Inc. | Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection |
JP5269086B2 (ja) * | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
JP5285709B2 (ja) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
WO2009089263A2 (en) * | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
US10039718B2 (en) * | 2008-05-02 | 2018-08-07 | Gilead Sciences, Inc. | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
WO2010073078A2 (en) * | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
SG173544A1 (en) * | 2009-02-06 | 2011-09-29 | Gilead Sciences Inc | Tablets for combination therapy |
AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
WO2010137032A2 (en) * | 2009-05-14 | 2010-12-02 | Matrix Laboratories Ltd. | Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts |
WO2011004389A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
US20120220571A1 (en) * | 2009-08-26 | 2012-08-30 | Wai John S | Hiv integrase inhibitors |
JP5758900B2 (ja) | 2009-09-30 | 2015-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンジルベンゼン誘導体の調製方法 |
EP2483286B1 (en) | 2009-09-30 | 2016-07-13 | Boehringer Ingelheim International GmbH | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
CA2777664C (en) | 2009-10-13 | 2014-06-10 | Johannes Wilhelmus J. Thuring | Macrocyclic integrase inhibitors |
EA201270651A1 (ru) | 2009-12-07 | 2013-01-30 | Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. | Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения |
RU2567385C2 (ru) | 2010-04-02 | 2015-11-10 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | Макроциклические ингибиторы интегразы |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
AU2011274323B2 (en) | 2010-07-02 | 2015-08-06 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as HIV antiviral compounds |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
AP2015008931A0 (en) | 2011-04-21 | 2015-12-31 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CA2850881C (en) | 2012-04-20 | 2021-02-16 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
CN104520275B (zh) * | 2012-08-03 | 2016-11-02 | 吉利德科学公司 | 用于制备整合酶抑制剂的方法和中间产物 |
CZ304984B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru |
CZ304983B6 (cs) | 2012-10-12 | 2015-03-11 | Zentiva, K.S. | Způsob výroby a nové intermediáty syntézy elvitegraviru |
US9216996B2 (en) | 2012-12-21 | 2015-12-22 | Gilead Sciences, Inc. | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
CA3109313A1 (en) | 2012-12-26 | 2014-07-03 | Societes Des Produits Nestle S.A. | Low density coated animal litter compositions |
PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CN113181161A (zh) | 2013-04-18 | 2021-07-30 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
CZ307255B6 (cs) * | 2013-07-11 | 2018-05-02 | Zentiva, K.S. | Nový způsob přípravy elvitegraviru |
JP6411491B2 (ja) | 2013-07-12 | 2018-10-24 | ギリアード サイエンシス インコーポレーテッド | 多環式カルバモイルピリドン化合物およびhiv感染症を処置するためのその使用 |
NO2865735T3 (ko) | 2013-07-12 | 2018-07-21 | ||
NO2717902T3 (ko) | 2014-06-20 | 2018-06-23 | ||
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
US10766863B2 (en) | 2014-11-17 | 2020-09-08 | Nirogyone Therapeutics, Inc. | Monocarboxylate transport modulators and uses thereof |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
CN107531727B (zh) | 2015-04-02 | 2019-11-29 | 吉利德科学公司 | 多环氨甲酰基吡啶酮化合物及其药物用途 |
WO2016193997A2 (en) * | 2015-06-03 | 2016-12-08 | Msn Laboratories Private Limited | Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof |
BR112018007631A2 (pt) | 2015-10-23 | 2018-11-06 | Nestec Sa | areias de baixa densidade para animais de estimação e métodos de fabricação e uso dessas areias para ani-mais de estimação |
RU2654062C2 (ru) * | 2016-07-14 | 2018-05-16 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3472859A (en) * | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
KR970704693A (ko) * | 1994-07-18 | 1997-09-06 | 나가히로 마오미 | 트리플루오로메틸퀴놀린카르복실산 유도체(trifluoromethylquinolinecarboxylic acid derivative) |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4826772A (ko) | 1971-08-11 | 1973-04-09 | ||
DE3501247A1 (de) * | 1985-01-16 | 1986-07-17 | Bayer Ag, 5090 Leverkusen | Aminoacrylsaeure-derivate |
US5591744A (en) * | 1987-04-16 | 1997-01-07 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
EP0319906A3 (en) * | 1987-12-11 | 1990-05-02 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them |
US4920120A (en) * | 1988-01-25 | 1990-04-24 | Warner-Lambert Company | Antibacterial agents |
DE3934082A1 (de) * | 1989-10-12 | 1991-04-18 | Bayer Ag | Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel |
DE4015299A1 (de) * | 1990-05-12 | 1991-11-14 | Bayer Ag | Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten |
IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
JP2993316B2 (ja) | 1992-05-27 | 1999-12-20 | 宇部興産株式会社 | アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤 |
NO304832B1 (no) | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
JPH06199635A (ja) | 1992-12-28 | 1994-07-19 | Kanebo Ltd | 化粧料 |
JPH06199835A (ja) | 1993-01-08 | 1994-07-19 | Hokuriku Seiyaku Co Ltd | 8−ジフルオロメトキシキノリン−3−カルボン酸誘導体 |
JPH06271568A (ja) | 1993-03-22 | 1994-09-27 | Hokuriku Seiyaku Co Ltd | 7−フェニルピペラジニルキノリン−3−カルボン酸誘導体 |
CA2187429A1 (en) | 1994-04-28 | 1995-11-09 | Junya Ohmori | N-(3-pyrrolidinyl)benzamide derivative |
JP2930539B2 (ja) | 1994-07-18 | 1999-08-03 | 三共株式会社 | トリフルオロメチルキノリンカルボン酸誘導体 |
JPH08183776A (ja) | 1994-12-28 | 1996-07-16 | Hideaki Yamaguchi | 金属の表面保護剤ならびにそれを用いた製造方法 |
US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
PT892801E (pt) * | 1996-04-12 | 2002-06-28 | Us Gov Health & Human Serv | Compostos derivados de acridona uteis como agentes antineoplasicos e antiretrovirais |
US6287550B1 (en) * | 1996-12-17 | 2001-09-11 | The Procter & Gamble Company | Animal care system and litter with reduced malodor impression |
US5989451A (en) | 1997-02-07 | 1999-11-23 | Queen's University At Kingston | Compounds and methods for doping liquid crystal hosts |
FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Icam−1産生阻害剤 |
KR20010013377A (ko) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
TW527355B (en) * | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
JPH1184556A (ja) | 1997-09-08 | 1999-03-26 | Konica Corp | ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法 |
GB9721964D0 (en) | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
GB9807903D0 (en) | 1998-04-14 | 1998-06-10 | Smithkline Beecham Plc | Novel compounds |
US6399629B1 (en) * | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
PE20011349A1 (es) | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
US6730682B2 (en) * | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
JP2004513134A (ja) | 2000-10-12 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類 |
EP1326610B1 (en) | 2000-10-12 | 2006-11-15 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
CN1232508C (zh) * | 2000-12-14 | 2005-12-21 | 宝洁公司 | 制取喹诺酮和二氮杂萘的环化方法步骤 |
AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
JP3616628B2 (ja) | 2001-03-01 | 2005-02-02 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物 |
JP4518302B2 (ja) | 2001-03-19 | 2010-08-04 | 日本化薬株式会社 | 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体 |
JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
JP3980842B2 (ja) | 2001-05-11 | 2007-09-26 | バブコック日立株式会社 | アンモニア含有排水の浄化装置および浄化方法 |
JP2003065807A (ja) | 2001-08-29 | 2003-03-05 | Mitsubishi Electric Corp | プロセスデータのトレンド表示方法および装置 |
JP3913037B2 (ja) | 2001-10-30 | 2007-05-09 | 三菱電機株式会社 | 赤外線検出器 |
TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
DK1564210T5 (da) * | 2002-11-20 | 2010-05-03 | Japan Tobacco Inc | 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer |
JP2004253231A (ja) | 2003-02-20 | 2004-09-09 | Pioneer Electronic Corp | プラズマディスプレイパネル |
US7531554B2 (en) * | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US8633219B2 (en) * | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
AU2007223260C1 (en) * | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
IN2014CN00532A (ko) * | 2006-03-06 | 2015-04-03 | Japan Tobacco Inc | |
TW200811153A (en) * | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
EP2644587A3 (en) * | 2006-09-12 | 2013-10-23 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
EP2197847B1 (en) * | 2007-09-12 | 2012-11-07 | Concert Pharmaceuticals Inc. | Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection |
WO2009089263A2 (en) | 2008-01-07 | 2009-07-16 | Ardea Biosciences Inc. | Novel compositions and methods of use |
SI23420A (sl) | 2010-07-22 | 2012-01-31 | Institut "Jožef Stefan" | Kostni vsadki z večslojno prevleko in postopek njihove priprave |
US11347056B2 (en) | 2018-08-22 | 2022-05-31 | Microsoft Technology Licensing, Llc | Foveated color correction to improve color uniformity of head-mounted displays |
WO2020040563A1 (ko) | 2018-08-23 | 2020-02-27 | 엘지이노텍 주식회사 | 센싱 장치 |
WO2020040561A1 (ko) | 2018-08-24 | 2020-02-27 | 한온시스템 주식회사 | 차량용 공조장치 |
-
2003
- 2003-11-20 DK DK03811532.5T patent/DK1564210T5/da active
- 2003-11-20 EP EP10011216A patent/EP2272516A3/en not_active Withdrawn
- 2003-11-20 AU AU2003302029A patent/AU2003302029B8/en active Active
- 2003-11-20 SI SI200331707T patent/SI1564210T1/sl unknown
- 2003-11-20 NZ NZ533641A patent/NZ533641A/en not_active IP Right Cessation
- 2003-11-20 KR KR1020047010082A patent/KR100665919B1/ko active Protection Beyond IP Right Term
- 2003-11-20 EP EP18166352.7A patent/EP3406596A1/en not_active Withdrawn
- 2003-11-20 MY MYPI20034478A patent/MY136173A/en unknown
- 2003-11-20 IL IL16254803A patent/IL162548A0/xx unknown
- 2003-11-20 US US10/492,833 patent/US7176220B2/en active Active
- 2003-11-20 AR ARP030104286A patent/AR042095A1/es active IP Right Grant
- 2003-11-20 CA CA2470365A patent/CA2470365C/en not_active Expired - Lifetime
- 2003-11-20 EP EP22158433.7A patent/EP4059923A1/en active Pending
- 2003-11-20 EP EP03811532A patent/EP1564210B9/en not_active Expired - Lifetime
- 2003-11-20 AT AT03811532T patent/ATE443048T1/de active
- 2003-11-20 PE PE2003001176A patent/PE20040840A1/es active IP Right Grant
- 2003-11-20 CZ CZ2004764A patent/CZ2004764A3/cs unknown
- 2003-11-20 BR BRPI0306214-7A patent/BRPI0306214B1/pt active IP Right Grant
- 2003-11-20 TR TR2004/01663T patent/TR200401663T1/xx unknown
- 2003-11-20 TW TW092132527A patent/TWI248928B/zh not_active IP Right Cessation
- 2003-11-20 SK SK266-2004A patent/SK2662004A3/sk not_active Application Discontinuation
- 2003-11-20 EP EP09169859A patent/EP2161258A3/en not_active Withdrawn
- 2003-11-20 ES ES03811532T patent/ES2329240T3/es not_active Expired - Lifetime
- 2003-11-20 PT PT03811532T patent/PT1564210E/pt unknown
- 2003-11-20 DE DE60329318T patent/DE60329318D1/de not_active Expired - Lifetime
- 2003-11-20 WO PCT/JP2003/014773 patent/WO2004046115A1/ja active IP Right Grant
-
2004
- 2004-06-08 ZA ZA2004/04537A patent/ZA200404537B/en unknown
- 2004-06-16 IL IL162548A patent/IL162548A/en active Protection Beyond IP Right Term
- 2004-07-02 MX MXPA04006553A patent/MXPA04006553A/es active IP Right Grant
- 2004-07-14 NO NO20043004A patent/NO327098B1/no not_active IP Right Cessation
-
2006
- 2006-01-18 HK HK06100829.1A patent/HK1080852A1/xx not_active IP Right Cessation
- 2006-06-05 US US11/446,128 patent/US8232401B2/en active Active
-
2009
- 2009-12-11 CY CY20091101301T patent/CY1110690T1/el unknown
-
2012
- 2012-06-20 US US13/528,688 patent/US20130172344A1/en not_active Abandoned
- 2012-07-03 AR ARP120102410A patent/AR087046A2/es unknown
-
2013
- 2013-07-12 LT LTPA2013018C patent/LTPA2013018I1/lt unknown
- 2013-11-07 HU HUS1300066C patent/HUS1300066I1/hu unknown
- 2013-11-07 NO NO2013015C patent/NO2013015I2/no unknown
- 2013-11-11 LU LU92307C patent/LU92307I2/fr unknown
- 2013-11-12 FR FR13C0061C patent/FR13C0061I2/fr active Active
- 2013-11-14 BE BE2013C063C patent/BE2013C063I2/fr unknown
- 2013-11-18 CY CY2013043C patent/CY2013043I1/el unknown
-
2014
- 2014-06-10 US US14/301,083 patent/US20150174117A1/en not_active Abandoned
-
2019
- 2019-05-10 US US16/409,728 patent/US20200101061A1/en not_active Abandoned
-
2022
- 2022-05-13 US US17/663,391 patent/US20230190730A1/en not_active Abandoned
- 2022-07-22 NO NO2022032C patent/NO2022032I1/no unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3472859A (en) * | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
KR970704693A (ko) * | 1994-07-18 | 1997-09-06 | 나가히로 마오미 | 트리플루오로메틸퀴놀린카르복실산 유도체(trifluoromethylquinolinecarboxylic acid derivative) |
Non-Patent Citations (1)
Title |
---|
1019970704693 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100665919B1 (ko) | 4-옥소퀴놀린 화합물 및 hiv 인테그라제 저해제로서의그의 용도 | |
JP3567162B1 (ja) | 4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用 | |
AU2005245296B2 (en) | Stable crystal of 4-oxoquinoline compound | |
JP4629104B2 (ja) | 4−オキソキノリン誘導体および抗hiv剤を含む併用剤 | |
US20060019906A1 (en) | Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor | |
KR101053811B1 (ko) | 6-(헤테로사이클-치환 벤질)-4-옥소퀴놀린 화합물 및 hiv 인테그라아제 억제제로서의 그의 용도 | |
US7745459B2 (en) | Quinolizinone compound and use thereof as HIV integrase inhibitor | |
CN100375742C (zh) | 4-氧代喹啉化合物及其用途 | |
RU2275361C2 (ru) | Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы | |
KR100866296B1 (ko) | 4―옥소퀴놀린 화합물의 안정한 결정체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
E90F | Notification of reason for final refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20131223 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141231 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151201 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161129 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181129 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191127 Year of fee payment: 14 |